| Field | Specification |
|---|---|
| Target | |
| Alternative names | Krueppel-like factor 13; Basic transcription element-binding protein 3; BTE-binding protein 3; Novel Sp1-like zinc finger transcription factor 1; RANTES factor of late activated T-lymphocytes 1; RFLAT-1; Transcription factor BTEB3; Transcription factor NSLP1; KLF13; BTEB3; NSLP1 |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | E.coli-derived human KLF13 recombinant protein (Position: K56-R260). |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody targets krueppel-like factor 13 (gene KLF13) in human, mouse and rat samples and is validated for Western blot, IHC, flow cytometry and ELISA. The predicted molecular weight is 31.2 kDa, and the supplier reports an observed band at about 38 kDa.
KLF13 is a Krüppel-like zinc finger transcription factor that binds GC-rich promoter elements. It can activate genes, including the chemokine RANTES (CCL5) in T cells and genes in red blood cell precursors, or repress them by competing with SP1 and recruiting Sin3A–HDAC1 corepressors. It is studied in T-cell biology, erythropoiesis and heart development.
| Target | Krueppel-like factor 13 (gene KLF13; UniProt Q9Y2Y9, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human, Mouse, Rat |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4 |
| Calculated MW | 31.2 kDa |
| Observed MW | 38 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.25–0.5 µg/mL (Human, Mouse, Rat) |
|---|---|
| IHC (paraffin sections) | 2–5 µg/mL (Rat) |
| Flow cytometry (fixed cells) | 1–3 µg/1×106 cells (Human, Mouse, Rat) |
| ELISA | 0.1–0.5 µg/mL |
Samples with a confirmed band (WB): human SH-SY5Y cells, human HeLa cells, human HEL cells, human HL-60 cells, human PC-3 cells, human Jurkat cells, rat thymus tissue, mouse thymus tissue.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with confirmed staining (IHC): rat thymus tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Samples with a confirmed signal (flow cytometry): HeLa cells, Neuro-2a cells, C6 cells.
Immunogen
Recombinant human KLF13 fragment (Lys56–Arg260), expressed in E. coli.
Reactivity Notes
The supplier lists reactivity with human, mouse and rat. UniProt places krueppel-like factor 13 in the nucleus. Tissue expression noted by UniProt (human): Ubiquitous. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
